ClinicalTrials.gg
CompletedNCT05376384OC-ESSUpdated Apr 17, 2024

Ovarian Cyst's Enucleation Spillage Score

An observational study in Ovarian Cysts and Spillage, sponsored by University of Campania Luigi Vanvitelli. Completed at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by University of Campania Luigi Vanvitelli · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
129
Ages
18 Years and older
Sex
Female
01

Study summary

Cystic enucleation is one of the most common conservative surgeries in gynecology; it is commonly performed by a minimally invasive approach such as laparoscopy. A high percentage of these surgeries (6-88 % of cases) are complicated by the cystic rupture with intra-abdominal spillage of its contents (spillage). This occurrence affects the surgical and prognostic outcome by lengthening the time of surgery, increasing the risk of postoperative infection or granulomatous peritonitis, of possible second manifestation of the pathology (example: endometriosis), and in the case of neoformation of a carcinomatous nature by leading to an increase in the stage of disease, exposing patients to a prognostic disadvantage and the need for adjuvant treatments also avoidable. In addition, the previous spillage may be associated with the adherent syndrome with repercussions on patients' morbidity and fertility. For these reasons, it is crucial to optimize the selection of patients who are candidates for cystic enucleation.

The present study aims to evaluate a series of ultrasound, medical history, and surgical-preoperative parameters to develop a predictive score for the risk of spillage during laparoscopic surgery. Prospective Observational Study. The study aims to enroll 156 patients.

02

Conditions studied

  • Ovarian Cysts
  • Spillage

Browse trials for

Keywords

  • ovarian cysts
  • laparoscopy
  • cyst enucleation
  • spillage
03

In context

Ovarian Cysts

80 studies on the registry are indexed under Ovarian Cysts; 16 are open to participants now.

This study's enrollment of 129 is below the median of 200 across 27 observational studies indexed under Ovarian Cysts.

Browse Ovarian Cysts studies →

Lead sponsor

University of Campania Luigi Vanvitelli is the lead sponsor of 174 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients in the Naples Metropolitan area, southern Italy, where our university hospital is located, suffering from adnexal cystic neoformation for which they need to undergo laparoscopic cystic enucleation surgery. Patients will receive the standard of care regardless of participation in the study, in which they will participate voluntarily and after signing informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients >18 years of age
  • Patients undergoing laparoscopic cystic enucleation
  • Patients who underwent pelvic ultrasound examination within 30 days prior to surgery
  • Patients who signed for the study
  • performance status \< 2

Exclusion criteria

Exclusion Criteria:

  • Pregnancy status
  • Patients with cardiological, neurological, or metabolic disorders not treated pharmacologically
  • Patients undergoing laparotomy conversion prior to enucleation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
129 participants (actual)
Target follow-up
1 Week
Patient registry
Yes

Groups and cohorts

  • Case

    Patients, over 18 years old, undergoing laparoscopic cyst enucleation surgery with an occasional, unanticipated finding of cyst rupture and intraoperative spillage

    Diagnostic Test: ultrasound parameters · Procedure: intraoperative parameters

  • Control

    Patients, over 18 years old, undergoing laparoscopic cystic enucleation surgery with the extraction of the intact operative specimen.

    Diagnostic Test: ultrasound parameters · Procedure: intraoperative parameters

Interventions

  • Diagnostic testultrasound parameters

    Annotation of ultrasonographic features of ovarian cyst. The parts examined are size, laterality, content, margins, and color score.

  • Procedureintraoperative parameters

    Annotation of intraoperative features of ovarian cyst. The characteristics under review are: surgeon experience, previous surgery, adhesions, and uterine manipulator use

06

What researchers measure

Primary outcomes

  1. Spillage Rate

    Identification of spillage rate during laparoscopic cystic enucleation in patients with the risk factors considered.

    Time frame: 12 months

07

Study locations

1 site
  • Università degli Studi della Campania Luigi Vanvitelli
    Naples, 80138, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Mar 2024, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2022
First posted
May 17, 2022
StartActual
May 12, 2022
Primary completionActual
Mar 31, 2024
CompletionActual
Apr 1, 2024
Last update
Apr 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05376384
Responsible party
Carlo Ronsini (Principal Investigator, University of Campania Luigi Vanvitelli) — Principal investigator
First posted
May 17, 2022
Start date
May 12, 2022
Primary completion
Mar 31, 2024
Completion
Apr 1, 2024
Last update
Apr 17, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion